Chau et al. conducted a single-arm, phase II trial that enrolled fourteen patients suffering from recurrent and/or metastatic ACC, who were treated with sunitinib (37.5 mg daily), a multi-targeted inhibitor of VEGFR, c-KIT, PGFR, ret proto-oncogene (RET) and FMS-like tyrosine kinase 3 (FLT3). This evidence concerns the gene FLT3 and adrenal cortex carcinoma.